SolasCure's Aurase Wound Gel Shows 22x Better Debridement and 7x Faster Healing in Chronic Wounds
核心洞察
SolasCure (搜索)'s Aurase Wound Gel (搜索) demonstrated 22 times more effective wound debridement and 7 times accelerated healing compared to current standard of care in Phase 2a clinical trials.
The enzymatic wound treatment combines a hydrogel with tarumase (搜索), targeting a $4.3 billion addressable market for advanced chronic wound care in the US alone.
SolasCure (搜索) is now seeking larger financing to advance to Phase 2b/3 clinical trials following the successful completion of its extension study.
SolasCure (搜索) has achieved a significant clinical breakthrough with its Aurase Wound Gel (搜索), demonstrating superior efficacy in treating chronic wounds (搜索) during Phase 2a clinical development. The enzymatic treatment showed 22 times more effective wound debridement and 7 times accelerated healing compared to the current standard of care in the control group.
Clinical Performance and Market Potential
The Aurase Wound Gel (搜索) combines a hydrogel with the enzymatic active ingredient tarumase (搜索), providing dual action on chronic wound debridement and healing. SolasCure (搜索) has successfully completed an extension study of Phase 2a clinical development, positioning the treatment as a potential best-in-class first-line therapy for chronic wounds (搜索).
The company identifies a total addressable market of approximately $4.3 billion in the US alone for advanced treatment of chronic wounds (搜索), highlighting the significant commercial opportunity for this innovative approach.
Next Steps in Clinical Development
Following these positive clinical results, SolasCure (搜索) is now seeking a larger financing round to secure funding for the next phases of clinical development, specifically targeting Phase 2b/3 trials. The company operates as an independent clinical development entity, with BRAIN Biotech AG (搜索) holding a 35% stake and maintaining additional production rights to the active pharmaceutical ingredient tarumase (搜索).
Adriaan Moelker, CEO of BRAIN Biotech, commented on the achievement: "I am really thrilled by the clinical data the SolasCure (搜索) team has been able to demonstrate. There is a large global need for innovation in advanced wound care. Aurase Wound Gel (搜索) has demonstrated to accelerate wound debridement and healing at the same time and has therefore the potential to become a best-in-class first line treatment for chronic wounds (搜索) with a large addressable market."
BRAIN Biotech's Role and Performance
BRAIN Biotech AG (搜索), the parent company with biotechnology expertise, originally invented the tarumase (搜索) enzyme and serves as an active partner in its commercialization. The company's BRAINBioIncubator segment, which includes the SolasCure (搜索) investment, benefited from a €1.0 million milestone income during the first quarter of fiscal year 2025/26.
The breakthrough represents a significant validation of BRAIN Biotech's enzyme development capabilities and its bioincubator model for advancing pharmaceutical innovations from laboratory discovery to clinical application.